These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 34403877

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.
    Chen L-p, Zhang L-f, Liu S, Hua H, Zhang L, Liu B-c, Wang R-r.
    Microbiol Spectr; 2024 Jun 04; 12(6):e0197923. PubMed ID: 38647315
    [Abstract] [Full Text] [Related]

  • 5. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P, Wang J, Li D, Ke W, Chen F, Hu X.
    J Nutr Biochem; 2020 Jul 04; 81():108363. PubMed ID: 32388250
    [Abstract] [Full Text] [Related]

  • 6. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
    Lee JE, Lee SM, Jung J.
    Phytomedicine; 2020 Dec 04; 79():153354. PubMed ID: 32992082
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The modulation of Luffa cylindrica (L.) Roem supplementation on gene expression and amino acid profiles in liver for alleviating hepatic steatosis via gut microbiota in high-fat diet-fed mice: insight from hepatic transcriptome analysis.
    Zhang L, Wang P, Shi M, Fang Z, Ji J, Liao X, Hu X, Chen F.
    J Nutr Biochem; 2020 Jun 04; 80():108365. PubMed ID: 32217466
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
    Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, Chu H, Du F, Zhu Q, Schnabl B, Huang K, Yang L, Hou X.
    Br J Pharmacol; 2018 Feb 04; 175(3):469-484. PubMed ID: 29139555
    [Abstract] [Full Text] [Related]

  • 13. Anti-NAFLD effect of defatted walnut powder extract in high fat diet-induced C57BL/6 mice by modulating the gut microbiota.
    Ren SM, Zhang QZ, Chen ML, Jiang M, Zhou Y, Xu XJ, Wang DM, Pan YN, Liu XQ.
    J Ethnopharmacol; 2021 Apr 24; 270():113814. PubMed ID: 33444725
    [Abstract] [Full Text] [Related]

  • 14. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X, Coker OO, Chu ES, Fu K, Lau HCH, Wang YX, Chan AWH, Wei H, Yang X, Sung JJY, Yu J.
    Gut; 2021 Apr 24; 70(4):761-774. PubMed ID: 32694178
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fructooligosaccharides attenuate non-alcoholic fatty liver disease by remodeling gut microbiota and association with lipid metabolism.
    Huang X, Chen Q, Fan Y, Yang R, Gong G, Yan C, Song Y, Zhang B, Xi S, Huang Y, Xu H.
    Biomed Pharmacother; 2023 Mar 24; 159():114300. PubMed ID: 36696803
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.